Five Years after Frontline Tyrosine-Kinase Inhibitor (TKI) Treatment Initiation for Chronic Myeloid Leukemia: What Does It Happen in a Real-Life Setting?
Daniela De Benedittis(Sapienza University of Rome), Roberto Latagliata(Ospedale di Belcolle), Matteo Molica(Sapienza University of Rome), Daniela Diverio(Policlinico Umberto I), Mauro Passucci(Sapienza University of Rome), Gioia Colafigli(Policlinico Umberto I), Chiara Lisi(Sapienza University of Rome), Fulvio Massaro(Policlinico Umberto I), Emilia Scalzulli(Policlinico Umberto I), Ida Carmosino(Policlinico Umberto I), Maria Giovanna Loglisci(Policlinico Umberto I), Elena Mariggiò(Policlinico Umberto I), Marco Mancini(Radboud University Nijmegen), Maria Lucia De Luca(Sapienza University of Rome), Massimo Breccia(Policlinico Umberto I), Sara Mohamed(Royal College of Surgeons in Ireland - Bahrain), Robin Foà(Sapienza University of Rome)
Cited by 0
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study
|The Lancet Oncology|2014|1.3k
Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia
|New England Journal of Medicine|2005|644
Th1/Th2/Th17/Treg cytokine imbalance in systemic lupus erythematosus (SLE) patients: Correlation with disease activity
|Cytokine|2015|505
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464